Currently, there are 89.94M common shares owned by the public and among those 80.11M shares have been available to trade.
The company’s stock has a 5-day price change of -2.79% and -1.55% over the past three months. CMRX shares are trading -10.13% year to date (YTD), with the 12-month market performance down to -11.05% lower. It has a 12-month low price of $0.75 and touched a high of $1.30 over the same period. CMRX has an average intraday trading volume of 190.56K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.64%, -4.69%, and -8.13% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Chimerix Inc (NASDAQ: CMRX) shares accounts for 41.20% of the company’s 89.94M shares outstanding.
It has a market capitalization of $75.27M and a beta (3y monthly) value of 1.03. The earnings-per-share (ttm) stands at -$0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.75% over the week and 7.55% over the month.
Earnings per share for the fiscal year are expected to decrease by -6.44%, and -4.39% over the next financial year.
Looking at the support for the CMRX, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on May 23, 2023, with the firm’s price target at $7. CapitalOne coverage for the Chimerix Inc (CMRX) stock in a research note released on September 07, 2022 offered a Overweight rating with a price target of $7. Maxim Group was of a view on April 29, 2021 that the stock is Buy, while Cowen gave the stock Outperform rating on April 23, 2021, issuing a price target of $10- $18. Wedbush on their part issued Outperform rating on March 31, 2021.
